Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
TE

NASDAQ · TELA

TELA Bio, Inc.

Healthcare · Medical - Devices

$0.81

Down-$0.11 (-11.95%)

Updated Nov 1, 2026, 7:34 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.56M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$0.50 – $1.50
Volume
330.11K
Avg. volume
183.24K

Price performance · TELA

TELA price history

1M range · 0 trading sessions · Daily adjusted prices

TELA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest TELA news

The latest Smart Investors Daily articles mentioning TELA.

Stock researchCompany · Overview

TELA research

Overview

Company profile and research snapshot.

Company profile

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.42
Implied upside
—
Analysts
—
TELA recent ratings
DateFirmRatingTarget
Sep 25, 2026Craig-HallumBuy—
Mar 27, 2026CitizensMarket Outperform—
Mar 25, 2026Lake StreetBuy—
Mar 25, 2026Piper SandlerNeutral—
Mar 25, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

TELA Bio to Announce Third Quarter 2026 Financial Results

MALVERN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2026 financial results on Tuesday, November 10, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conf

Yahoo · Oct 19, 2026

TELA Bio (TELA) Stock Sees Fair Value Cut As Analysts Weigh New Leadership Risks

The fair value estimate for TELA Bio has shifted from US$2.25 to US$1.90, which points to a lower assessed price target based on the latest analyst work. This reset lines up with a split analyst view, where some see new leadership as a possible turning point while others focus on execution risk and the need for proof before assigning a higher value. As you read on, you will see how these changing expectations shape the current story and what to watch as the TELA Bio narrative evolves. Analyst...

Yahoo · Oct 5, 2026

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product. Liora is a fully resorbable surgical mesh device for soft tissue reinforcement that will enable TELA Bio to expand its footprint in the s

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By